Addiction Toxicology Case Conference - November 2025
-
Register
- Non-member - Tier I - Free!
- Non-member - Tier II - Free!
- Non-member - Tier III - Free!
- Non-member - Tier IV - Free!
- Member - Tier I - Free!
- Member - Tier II - Free!
- Member - Tier III - Free!
- Member - Tier IV - Free!
Nicotine
Friday, November 7, 2025
1:00-2:00pm ET
Case 1: Adolescent Oral Nicotine Use: Early Detection and Parental Concerns
Case 2: Vaping Initiation and Dependence in Non-Traditional Users
Learning Objectives
- Describe 3 different FDA approved treatments for nicotine use disorder and list common side effects associated with the use of each treatment
- Describe two demographics in which nicotine use has increased rapidly in recent years, including the rising use of oral nicotine products (e.g., Zyn) among young men, and explain the underlying factors contributing to these trends.
- Identify the adverse health outcomes and addiction disorders associated with tobacco and nicotine use.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
JoAn Laes, MD, DFASAM, FACMT
Addiction Staff Physician
Abbott Northwestern Hospital, Allina Health
JoAn Laes, MD, DFASAM, FACMT is an addiction medicine physician in Minneapolis, Minnesota, focusing on inpatient addiction medicine and toxicology consultation as well as experience in outpatient treatment of opioid and other substance use disorders. She is also a core medical toxicology faculty for the Minnesota Poison Center, Minneapolis, Minnesota, and medical director for Missions Inc. Detox facility in Plymouth, Minnesota. She is board certified in Internal Medicine, Medical Toxicology, and Addiction Medicine. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.
Ismael David Yanga III, MD
Chief Medical Officer
Henry Ford Brighton Center for Recovery
Dr. Ismael David Yanga III is the Chief Medical Officer at the Henry Ford Brighton Center for Recovery. He is board-certified in Family Medicine and Addiction Medicine and brings extensive experience in clinical leadership and the treatment of substance use disorders. Dr. Yanga earned his medical degree from Wayne State University School of Medicine and completed his residency in Family Medicine at the University of Michigan Hospitals & Health Centers.
In his role, Dr. Yanga oversees clinical operations and quality of care, guiding multidisciplinary teams to provide comprehensive, evidence-based addiction treatment.
Holly A. Russell, MD
Associate Professor Family Medicine and Director of Opioid Safety
University of Rochester Medical Center
Dr. Russell earned a B.S. in Biochemistry from Boston College, and went on to serve in the Jesuit Volunteer Corps for a year in Oakland, California working as a counselor and nursing assistant at a residential treatment center for adolescents with substance abuse disorders. She obtained her M.D. degree with a Distinction in Community Service from the University of Rochester in 2007, and completed internship and residency in Family Medicine with an Area of Concentration in Research at Lancaster General Hospital in Lancaster, Pennsylvania. In 2010, she returned to the University of Rochester and completed a faculty development fellowship and a Master's of Clinical Investigation.
Dr. Russell is Board Certified in Family Medicine and Addiction Medicine and is the founder and director of the Addiction Medicine program at Highland Family Medicine. Dr. Russell is the Director of Opioid Safety for the University of Rochester Medical Center. She is also the Medical Director at Delphi Rise, a community substance use treatment program.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.
Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
Key:
Complete
Next
Failed
Available
Locked